Mesa Laboratories/$MLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mesa Laboratories
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Ticker
$MLAB
Sector
Primary listing
Employees
730
Headquarters
Website
MLAB Metrics
BasicAdvanced
$436M
-
-$0.11
0.86
$0.64
0.81%
Price and volume
Market cap
$436M
Beta
0.86
52-week high
$155.12
52-week low
$55.45
Average daily volume
155K
Dividend rate
$0.64
Financial strength
Current ratio
0.657
Quick ratio
0.415
Long term debt to equity
46.107
Total debt to equity
107.212
Interest coverage (TTM)
1.27%
Profitability
EBITDA (TTM)
39.293
Gross margin (TTM)
62.31%
Net profit margin (TTM)
-0.26%
Operating margin (TTM)
5.89%
Effective tax rate (TTM)
106.84%
Revenue per employee (TTM)
$330,000
Management effectiveness
Return on assets (TTM)
2.04%
Return on equity (TTM)
-0.38%
Valuation
Price to revenue (TTM)
1.776
Price to book
2.52
Price to tangible book (TTM)
-3.86
Price to free cash flow (TTM)
12.913
Free cash flow yield (TTM)
7.74%
Free cash flow per share (TTM)
6.131
Dividend yield (TTM)
0.81%
Forward dividend yield
0.81%
Growth
Revenue change (TTM)
8.33%
Earnings per share change (TTM)
-99.75%
3-year revenue growth (CAGR)
6.64%
10-year revenue growth (CAGR)
12.74%
3-year earnings per share growth (CAGR)
-27.54%
10-year earnings per share growth (CAGR)
-27.55%
10-year dividend per share growth (CAGR)
0.16%
What the Analysts think about MLAB
Analyst ratings (Buy, Hold, Sell) for Mesa Laboratories stock.
Bulls say / Bears say
FY25 total revenues were $240.98 million, up 11.5% year-over-year, with non-GAAP adjusted operating income rising 12.3% to $56.7 million, demonstrating strong multi-division growth and improved operational efficiency (GlobeNewswire)
Mesa completed the integration of the GKE acquisition in nine months, outperforming initial revenue and profitability targets and strengthening the scale and cross-selling abilities of its SDC division (GlobeNewswire)
In Q1 FY26, the Sterilization and Disinfection Control segment achieved 7.5% core organic revenue growth and a 370 basis point gross margin improvement, supported by strong order fulfillment and clearing of backlog (Mesa Labs investors)
The Clinical Genomics division’s core organic revenues dropped 10.7% in Q1 FY26, mainly because China sales fell 69% amid macroeconomic and regulatory challenges (Mesa Labs investors)
Biopharmaceutical Development revenues decreased by 7.0% on a core organic basis in Q1 FY26 owing to order timing and shipping delays, highlighting the segment's variability (Mesa Labs investors)
Wells Fargo lowered its price target for MLAB from $100 to $67, and Wall Street Zen downgraded the stock to 'hold', signaling analyst concerns over valuation and short-term growth prospects (MarketBeat)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MLAB Financial Performance
Revenues and expenses
MLAB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for Mesa Laboratories stock?
Mesa Laboratories (MLAB) has a market cap of $436M as of October 25, 2025.
What is the P/E ratio for Mesa Laboratories stock?
The price to earnings (P/E) ratio for Mesa Laboratories (MLAB) stock is 0 as of October 25, 2025.
Does Mesa Laboratories stock pay dividends?
Yes, the Mesa Laboratories (MLAB) stock pays dividends to shareholders. As of October 25, 2025, the dividend rate is $0.64 and the yield is 0.81%. Mesa Laboratories has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Mesa Laboratories dividend payment date?
The next Mesa Laboratories (MLAB) dividend payment is scheduled for December 15, 2025.
What is the beta indicator for Mesa Laboratories?
Mesa Laboratories (MLAB) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.